Lipocine is trading at $1.44, down 10.00%, amid a broad market selloff.
- Reuters reported the Nasdaq slid more than 2% as mega-cap earnings did little to ease AI concerns and rising oil added to market unease.
- No Lipocine-specific announcement for October 22 was found. The latest investor-relations release listed in search results was its October 7 Health Canada approval announcement.